San Diego-based Biolinq, a digital health company specializing in minimally invasive continuous glucose monitoring, raised $10 million in Series A financing. The round was led by M Ventures, in collaboration with Hikma Ventures.
Biolinq is currently working on a skin applied, minimally-invasive electrochemical biosensor platform for diabetes patients, which analyzes biomarkers in the...
Digital diabetes management company Glooko and device maker Dexcom have expanded their partnership, effectively creating on-demand access to continuous glucose monitor data for both physicians and patients who use the two companies’ products.
Glooko and Dexcom began working together in June 2015, when Glooko first began integrating CGMs and insulin pumps into its platform. But for the past two...
Medical device maker Medtronic has teamed up with Fitbit to integrate physical activity data with blood glucose levels into one streamlined application.
People living with type 2 diabetes who use Medtronic's iPro2 continuous glucose monitoring system and its companion app, iPro2 myLog, will now be able to have their Fitbit data automatically synced to the app, enabling them to easily see the...
Two diabetes management companies, Mountain View, California-based Glooko and Gothenburg, Sweden-based Diasend, will merge into a unified company, leveraging the global capabilities of Diasend and the user-friendly platform of Glooko.
The joint solution, which will operate under the Glooko name, will now serve 4,000 diabetes clinics in 23 countries across 15 languages. The joint platform...
An FDA advisory panel has voted in favor of recommending a change to the intended use of Dexcom’s G5 Continuous Glucose Monitor (CGM). The G5 had already been FDA-approved, but with limitations as an adjunctive device, meaning it could only be used for tracking and trending interstitial fluid gluocose concentrations rather than as a full replacement for a traditional fingerstick blood glucose...
The old Dexcom Share, with charging cradle.
Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor data to be transferred directly to a user's smartphone, as well as the smartphones of up to five friends or caretakers.
Dexcom Share got clearance in...
Germantown, Maryland-based continuous glucose monitor developer Senseonics raised $20 million from existing investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, and New Enterprise Associates. This brings the company's total funding to at least $84 million to date.
Senseonics will use the funds to obtain a CE mark and start investigational device exemption (IDE) ...
